CALR and cancer: Inhibiting ecto-CRT exposure by either knocking down CRT or disrupting its trafficking to the cell surface has been shown to deprive the immunogenicity of dying tumour cells treated with anthracycline.99 Conversely, the introduction of exogeneous CRT restores the immunogenicity of non-immunogenic dying cancer cells.